A new drug called daraxonrasib has achieved what was once thought impossible: shutting down the KRAS protein that drives most pancreatic cancers. Credit: AI/ScienceDaily.com For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis. Pancreatic cancer is so deadly in part because there are no effective screening tests, and it